HCV Treatment
EASL 2015: Shortening Triple Therapy to 6 Weeks Is Effective for Some Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 12 May 2015 00:00
- Written by Keith Alcorn
Shortening direct-acting antiviral therapy to 6 weeks for easier-to-treat patients without liver cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with HCV genotype 1 infection, according to results of a study evaluating grazoprevir, elbasvir, and sofosbuvir (Sovaldi) in short treatment courses. Moreover, for people with HCV genotype 3 but no cirrhosis, an 8-week course of treatment was only marginally less effective than a 12-week course, even though genotype 3 infection is considered harder to treat.
EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
EASL 2015: Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 May 2015 00:00
- Written by Liz Highleyman
Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of genotype 1 chronic hepatitis C patients with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. The sustained response rate in HCV-TARGET fell to 39% for genotype 3, but another study found that 70% of genotype 3 patients with decompensated cirrhosis could be cured with sofosbuvir plus daclatasvir (Daklinza), while sofosbuvir/ledipasvir (Harvoni) cured up to 86% of genotype 1 patients.
EASL 2015: Gilead Triple Combination Cures Easy-To-Treat Hepatitis C Patients in 6 Weeks
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 May 2015 00:00
- Written by Liz Highleyman
A 6-week regimen of sofosbuvir (Sovaldi) plus 2 experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver cirrhosis, according to a poster presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. A 4-week regimen was not effective for any group, however, and 6 weeks appears inadequate for harder-to-treat patients. Other studies showed that the new drugs -- GS-5816 (velpatasvir) and GS-9857 -- are also active against other HCV genotypes.
Coverage of the 2015 EASL International Liver Congress
- Details
- Category: HCV Treatment
- Published on Tuesday, 05 May 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress (EASL 2015) in Vienna, April 22-26, 2015.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications.
International Liver Congress website
5/5/15
More Articles...
- EASL 2015: Paritaprevir and Ombitasvir Are Effective for Japanese Patients with HCV Genotype 1b
- EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment
- EASL 2015: Grazoprevir/ Elbasvir Combo Cures 99% of Hepatitis C Patients with Chronic Kidney Disease
- EASL 2015: Sofosbuvir-based Treatment Is Safe and Effective in Patients with Advanced Kidney Disease
Web Design and Development by